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http://www.biomedcentral.com/1471-2350/14/100RESEARCH ARTICLE Open AccessDefining the contribution of SNPs identified in
asthma GWAS to clinical variables in asthmatic
children
Asif S Tulah1,3, John W Holloway2 and Ian Sayers1*Abstract
Background: Asthma genome-wide association studies (GWAS) have identified several asthma susceptibility genes
with confidence; however the relative contribution of these genetic variants or single nucleotide polymorphisms
(SNPs) to clinical endpoints (as opposed to disease diagnosis) remains largely unknown. Thus the aim of this study
was to firstly bridge this gap in knowledge and secondly investigate whether these SNPs or those that are in
linkage disequilibrium are likely to be functional candidates with respect to regulation of gene expression, using
reported data from the ENCODE project.
Methods: Eleven of the key SNPs identified in eight loci from recent asthma GWAS were evaluated for association
with asthma and clinical outcomes, including percent predicted FEV1, bronchial hyperresponsiveness (BHR) to
methacholine, severity defined by British Thoracic Society steps and positive response to skin prick test, using the
family based association test additive model in a well characterised UK cohort consisting of 370 families with at
least two asthmatic children.
Results: GSDMB SNP rs2305480 (Ser311Pro) was associated with asthma diagnosis (p = 8.9×10-4), BHR (p = 8.2×10-4)
and severity (p = 1.5×10-4) with supporting evidence from a second GSDMB SNP rs11078927 (intronic). SNPs
evaluated in IL33, IL18R1, IL1RL1, SMAD3, IL2RB, PDE4D, CRB1 and RAD50 did not show association with any
phenotype tested when corrected for multiple testing. Analysis using ENCODE data provides further insight into the
functional relevance of these SNPs.
Conclusions: Our results provide further support for the role of GSDMB SNPs in determining multiple asthma
related phenotypes in childhood asthma including associations with lung function and disease severity.
Keywords: Asthma, ENCODE, eQTL, GWAS, Clinical endpointsBackground
Asthma is a complex respiratory disease with susceptibility
involving the interplay between genetic and environmental
factors [1]. The chronic inflammation of the airways is
characterised by reversible airflow obstruction and in-
creased hyperresponsiveness of the airways. Genome-wide
association studies (GWAS) are currently the preferred
method for the identification of genetic determinants in
complex multifactorial diseases such as asthma. These
studies have the advantage of being able to identify* Correspondence: ian.sayers@nottingham.ac.uk
1Division of Respiratory Medicine, Queen’s Medical Centre, University of
Nottingham, Nottingham NG7 2UH, United Kingdom
Full list of author information is available at the end of the article
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Commons Attribution License (http://creativec
reproduction in any medium, provided the orpolymorphisms with small effect sizes and localise smaller
susceptibility regions due to linkage disequilibrium (LD).
The first GWAS for asthma was completed involving 994
childhood-onset asthma patients and 1,243 non-asthma
controls and identified single nucleotide polymorphisms
(SNPs) within chromosome 17q21 spanning the ORMDL3/
GSDMB genes [2]. These SNPs showed highly significant
association with childhood asthma and were also repli-
cated in two independent cohorts [2]. A study in an Ice-
landic cohort showed significant association with asthma
and a SNP in IL1RL1 [3] and SNPs in PDE4D have also
shown association with genome-wide significance with
asthma [4]. IL-13 and RAD50 on 5q31.1 and the HLA-DR/
DQ locus at 6p21.3 have been implicated by Li et al. [5].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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IL2RB and CRB1 have been proposed by other GWAS
using large scale discovery and replication approaches
[6,7]. However, due to the phenotype used for case defin-
ition, which is often a physician diagnosis or self-report of
asthma, there remains a need to determine the contribu-
tion of these polymorphisms to clinically relevant end-
points in asthma. This will provide a greater insight into
the mechanisms altered in individuals carrying the rele-
vant risk alleles.
One problem that arises from GWAS is that LD patterns
can result in multiple polymorphisms at a locus being as-
sociated with disease phenotype, even if only one of them
is causal. A problem therefore exists in the identification
of potential causal variants. This can be simply analysed
for polymorphisms within coding regions, as they could
potentially affect the polypeptide structure and function
and those SNPs in regulatory or intronic regions could
affect splice site motifs, transcriptional regulation or RNA
stability [8,9]. However, many GWAS have implicated
polymorphisms in non transcribed regions far away from
annotated genes, where their role is likely to be regulatory
[10]. The ENCODE project was established to identify all
the functional elements such as protein binding sites, tran-
scripts (coding and non coding) and chromatin marks in
the human genome. This represents a valuable resource to
provide additional meaning to association data provided
from GWAS [11,12]. Taken in consideration with LD data
from the 1000 Genomes project [13], computational ana-
lysis will enable assignment of more meaningful potential
function to SNPs identified from GWAS or those SNPs
which are in LD with a GWAS associated SNP [10], to
help better prioritise SNPs for functional analysis.Table 1 Key SNPs identified in asthma GWAS included in the
Gene
SNP
Key SNP Non-coded Coded Location MAF*
Allele Allele (Contro
GSDMB rs2305480 C T Ser311Pro 0.45
GSDMB rs11078927 C T intron 0.45/0.4
IL33 rs1342326 T G 5′ region 0.16
IL33 rs3939286 G A 5′ region 0.25/0.2
IL18R1 rs3771166 C T intron 0.38
IL1RL1 rs1420101 G A intron 0.37/0.4
SMAD3 rs744910 A G intron 0.49
IL2RB rs2284033 A G intron 0.44
PDE4D rs1588265 A G intron 0.34/0.2
CRB1 rs2786098 C A intron 0.15
RAD50 rs2244012 T C intron 0.21
Previous GWAS associations include; a chromosome 17 locus (orm1-like protein3 (O
(interleukin 18 receptor (IL18R)/interleukin 1 receptor like 1 (IL1RL1)), mothers again
(IL2RB), phosphodiestase 4D, cAMP specific (PDE4D), a chromosome 1 locus (Crumb
MAF minor allele frequency, *a single MAF is shown where the original paper only r
the original study (referenced).The aim of the present study was to complete a SNP
for SNP analysis of the key variants identified in the
Caucasian population meeting genome-wide significance
and/or replication identified 2007–2011 on clinical vari-
ables underlying asthma (Table 1). As these SNPs have
previously shown genome-wide association, we also
sought to investigate the potential functional significance
of these eleven SNPs and those in LD (with these SNPs)
by mining the ENCODE dataset [14] and also investigating
whether they show association with expression quantita-
tive trait loci (eQTL).
Methods
Asthma cohort characteristics
The asthma family cohort was made up of United Kingdom
families from the Southampton and Nottingham areas
(n = 370 families were used in this study) (Table 2). From
the Southampton area, 341 Caucasian families (n = 1508)
with at least two biological siblings with physician diag-
nosed asthma were recruited. This cohort has been de-
scribed in detail previously [15]. Baseline FEV1 (forced
expiratory volume in one second) was measured as best of
three values within 5% performed using Vitalograph dry-
wedge bellows spirometer (Vitalograph Ltd, Buckingham,
UK). This was determined 14 days after respiratory tract
infection or use of bronchodilator or anti-allergic medica-
tion. 46 Caucasian families (n = 184) with at least two bio-
logical siblings with physician diagnosed asthma were
recruited from the Nottingham area [15]. FEV1 was de-
fined as the best of three values. All subjects were classi-
fied according to British Thoracic Society Step Guidelines
(BTS steps, ranging from step 1 to step 5) based on phys-
ician prescribed medication [16]. Ethical approval for thecurrent analyses
P-value Phenotype/Reference MAF in UK families
l/case)
6E-23 Asthma (childhood) [2,6] 0.43
0 7.4E-07 Asthma [2,6] 0.43
9E-10 Asthma [6] 0.17
8 5.3E-06 Asthma [3] 0.27
3E-09 Asthma [6] 0.38
0 5.5E-12 Asthma [3] 0.38
4E-09 Asthma [6] 0.48
1.1E-08 Asthma [6] 0.43
3 4.3E-07 Asthma [4] 0.29
9.3E-11 Asthma [7] 0.22
3.05E-07 Asthma [5] 0.18
RMDL3)/gasdermin B (GSDMB)), interleukin 33 (IL33), a chromosome 2 locus
st decaptentaplegic drosophila homolog 3 (SMAD3), and IL2 receptor beta
s homolog 1 precursor (CRB1)) and RAD50, S. Cerevisiae, homolog of (RAD50).
eported the MAF in all subjects. The p-value stated is for asthma association in
Table 2 Clinical characteristics of UK families
Pedigrees Sibling 1 Sibling 2
Age (mean years), ±SD 26.2 ± 1.6 13.3 ± 4.4 10.3 ± 4.6
Gender (% female) 50.8 54.6 53.7
Asthma (%, doctor diagnosed) 61.6 100 100
FEV1 (% predicted, ±SD) ND 95.4 ± 15.6 96.2 ± 14.9
Positive skin prick test (%) 62.5 73.9 65.1
Log total serum IgE (mean ± SD) 2.04 ± 0.7 2.33 ± 0.7 2.33 ± 0.7
Eczema (%, questionnaire) 41.1 53.5 55.1
Hay fever (%, questionnaire) 50.2 64.9 47.4
BTS (%) step 1 19.1 24.9 23.8
• Step 2 32.5 52.7 55.7
• Step 3 6.1 11.6 10.2
• Step 4 1.8 4.6 1.4
• Step 5 2.9 4.6 5.3
PC20 (4 mg/ml,%) 46.9 59.9
n 1578 370 361
The recruitment and clinical characterisation of these subjects has been
extensively described elsewhere [15]. PC20 (4 mg/ml, %) only available in
Southampton families.
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and South West Hampshire and the Portsmouth and South
East Hampshire Local Research Ethics Committees and
for the Nottingham subjects, the Nottingham University
Medical School Ethics Committee. Written informed con-
sent for study participation was obtained from participants
(from the parent/guardian for the children).
SNP selection and genotyping
Eleven SNPs were chosen that have been identified from
asthma GWAS identified 2007–2011 (Table 1). These
were in eight loci; ORMDL3/GSDMB, IL33, IL18R/
IL1RL1, SMAD3, IL2RB, PDE4D, CRB1 and RAD50.
SNPs were genotyped using KASPar technology by
KBiosciences (Hertfordshire, UK). For quality control of
genotyping data, Chi square was used to test for any de-
viation between the observed genotype frequencies and
the expected, under the Hardy Weinberg Equilibrium.
Association analyses
Association analysis in the family cohorts between the
GWAS SNPs and asthma-related traits was conducted
using the family based association test (FBAT) software
(version 1.5.1) [17] in the additive model. Clinically rele-
vant endpoints including; asthma diagnosis, Forced
Expiratory Volume in one second (FEV1% Predicted),
bronchial hyperresponsiveness to methacholine (BHR),
British Thoracic Society (BTS) defined severity [18] and
atopy (positive response to skin prick test to any one of a
panel of allergens as outlined [15]). We completed power
calculations based on the method of Risch & Merikangas[19]. There was between 0.93 and 0.98 power to detect an
association with asthma with a significance level of p = 0.05
and a relative risk of 1.5. There was between 0.51 and 0.69
power to detect an association with p = 0.05 and a relative
risk of 1.25 (calculations based on minor allele frequency
(min 0.17 to max 0.48 observed). Power curves for these
MAF are provided in Additional file 1. To address mul-
tiple testing, we used Bonferonni correction, which con-
sidered p < 9.1×10-4 significant. This was based on our
eleven genotyped SNPs analysed for five phenotypes
(0.05/55 total tests = 9.1×10-4 as a threshold p-value).
Bioinformatic analysis of genotyped SNPs
HaploReg [14] (a web based tool) was used to provide
information about the sequence surrounding a SNP. It
has been developed to mine chromatin state information
from nine human cell lines; GM12878, H1, HMEC,
HSMM, HepG2, Huvec, K562, NHEK and NHLF. The
tool provides information on SNPs that are in LD with
the queried SNP (r2 was set to 1 for these analyses and
the population chosen for analyses was of European des-
cent) and also gives information on which of these SNPs
lie in enhancer histone marks, DNase sites and protein
binding regions. It can also inform on the conservation
of the relevant sequence and any changes to regulatory
motifs based on the SNP allele changes. Each of the
eleven genotyped SNPs were entered into HaploReg and
analysis was completed with r2 = 1. A more detailed ana-
lysis was completed for any SNP which showed signifi-
cant association in the population study.
We used the program mRNA by SNP browser (version
1.0.1) to investigate whether any of the GWAS SNPs ge-
notyped as part of this study were associated with re-
gions of known asthma expression quantitative trait loci
(eQTL). This program incorporates a database of eQTL
from asthma studies and provides a graphical output to
browse data from GWAS. It provides association data
between 54,675 transcripts and 406,912 SNPs. Statistics
are provided for those SNPs with association p < 0.001.
We used the program to search for each SNP in turn by
inputting either the gene name or the SNP rs number,
looking to see whether the association reached genome-
wide significance (p < 10-8) [20]. We also used the eQTL
browser from the University of Chicago (http://eqtl.uchicago.
edu/cgi-bin/gbrowse/eqtl/) which considers eQTLs from
different tissue sources. A second stage of this analysis was
to investigate whether these same SNPs showed genome-
wide association with eQTL from a genome-wide search in
1,111 human lung samples [21].
Results
Clinical characteristics and genotyping
Clinical characteristics for the asthma families are shown
in Table 2. Mean age was 13.3 years and 10.3 years old,
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and % atopy (SPT) was 73.9% and 65.1% for sibling 1
and 2 respectively. These asthmatic children had pre-
dominantly mild-moderate disease as outlined by BTS
guidelines. Genotyping was completed using KASPar
(KBioscience) and quality control completed as outlined
in previous studies [15]. All SNPs were in Hardy Weinberg
equilibrium and allele frequencies in the UK families were
similar to those previously reported (Table 1).Association with asthma, FEV1 and BHR
A GSDMB SNP at the 17q21 locus, rs2305480 (Ser311Pro)
was associated with asthma diagnosis, with the Tallele con-
ferring risk to develop asthma as previously reported [6]
(p = 8.9×10-4, z = −3.23) (Table 3). Another GSDMB SNP
rs11078927 (intronic) showed similar findings with asthma
but did not reach statistical significance (p = 9.5×10-4,
z = −3.23) although this SNP was significantly associ-
ated with FEV1 (% Predicted) (p = 8.7×10
-4, z = −3.33).
Significant association was also observed with rs2305480
(GSDMB, Ser311Pro) and BHR (PC20 methacholine,
4 mg/ml) (p = 8.2×10-4, z = −3.35). No other SNP associ-
ation survived correction for multiple testing (Table 3).Association with asthma severity and atopy
Both GSDMB SNPs showed significant association with
severity of disease defined by BTS steps (1–5), both with
the same direction of association; rs2305480 (p = 1.5×10-4,
z = 3.79) and rs11078927 (p = 2.2×10-4, z = −3.70). No
other SNP association survived correction for multiple
testing (Table 4).Table 3 Association of key GWAS SNPs with asthma diagnosis,
to methacholine
SNP Gene Asthma Z P
Fam Score value
rs2305480 C/T GSDMB 265 −3.323 8.9×10-4
rs11078927 C/T GSDMB 272 −3.305 9.5×10-4
rs1342326 T/G IL33 176 +1.114 0.265
rs3939286 G/A IL33 198 +0.412 0.680
rs3771166 C/T IL18R1 263 −1.475 0.140
rs1420101 G/A IL1RL1 261 +0.899 0.369
rs744910 A/G SMAD3 264 +0.116 0.907
rs2284033 A/G IL2RB 262 +0.825 0.409
rs1588265 A/G PDE4D 233 −0.380 0.703
rs2786098 C/A CRB1 202 −1.702 0.089
rs2244012 A/G RAD50 187 +0.953 0.340
FBAT was used to test for association using the additive model [17]. SNP single nuc
analysis (≥10 families). Asthma = Doctor diagnosed asthma, FEV1 = FEV1 percent pre
Families, Bonferroni correction, P < 9.1×10-4 considered significant (bold).Bioinformatic analysis of SNPs using data from ENCODE
We sought to investigate whether data collected from
the ENCODE Consortium [12] could enrich the poten-
tial functional significance of our genotyped GWAS as-
sociated SNPs and also those SNPs which were in LD
(Table 5). The two GSDMB SNPs were found to be in
the same LD block (r2 = 1), with 24 other SNPs.
rs2244012 (RAD50/intronic) was found to be in an LD
block with 50 other SNPs. The other genotyped SNPs
were in smaller LD blocks. Most of our genotyped SNPs
analysed were found to have at least one SNP (in their
LD block) existing in an enhancer histone mark site,
DNase site or a region where protein binding consensus
sequences exist, highlighting a potential functional effect
of these particular SNPs. There was evidence for LD
SNPs altering regulatory motifs, with 14 SNPs in the
GSDMB LD block and 25 SNPs in the RAD50 LD block
the highest numbers (Table 5).
Analyses of asthma associated GSDMB SNPs using
ENCODE data
As the two GSDMB SNPs (rs2305480/Ser311Pro and
rs11078927/intronic) showed significant association in
our study, we sought to further investigate potential
functional implications using the ENCODE dataset.
These two GSDMB SNPs themselves were not predicted
to be important from a regulatory role, however they
were in a LD block with 24 other SNPs. Almost all of
the SNPs in this LD block were in non-coding/intronic
regions, with the exception of rs10852935, which is a
synonymous polymorphism in ZPBP2 and the genotyped
rs2305480/Ser311Pro (Table 6). Twenty four of these
SNPs were not conserved (according to the GERPpercent predicted FEV1 and bronchial hyperresponsiveness
FEV1 Z P BHR Z P
Fam Score value Fam Score value
274 −3.247 1.1×10-3 240 −3.345 8.2×10-4
278 −3.330 8.7×10-4 244 −3.238 1.2×10-3
180 +1.266 0.205 156 +1.412 0.158
204 +0.544 0.586 176 +0.693 0.489
270 −1.637 0.102 228 −1.416 0.157
264 +0.658 0.511 223 +0.737 0.461
271 +0.823 0.411 234 −0.166 0.868
267 +0.416 0.677 233 +0.778 0.436
239 −0.056 0.956 205 −0.506 0.613
204 −1.324 0.185 178 −2.377 0.017
189 +0.659 0.510 164 +1.075 0.282
leotide polymorphism, MAF minor allele frequency, Fam number of families in
dicted, BHR = PC20 (methacholine 4 mg/ml) only available in Southampton
Table 4 Association of key GWAS SNPs with asthma severity defined by BTS steps and atopy
SNP Gene Severity Z P SPT Z P
Fam Score value Fam Score value
rs2305480 C/T GSDMB 272 −3.791 1.5×10-4 220 −3.164 1.6×10-3
rs11078927 C/T GSDMB 277 −3.701 2.2 ×10-4 227 −3.133 1.7×10-3
rs1342326 T/G IL33 180 +1.378 0.168 144 +2.585 9.7×10-3
rs3939286 G/A IL33 204 +0.347 0.729 164 +2.146 0.032
rs3771166 C/T IL18R1 269 −2.021 0.043 219 −1.683 0.092
rs1420101 G/A IL1RL1 263 +1.577 0.115 218 +0.449 0.653
rs744910 A/G SMAD3 268 +0.386 0.699 215 +0.157 0.875
rs2284033 A/G IL2RB 268 +1.233 0.218 216 +1.265 0.206
rs1588265 A/G PDE4D 235 −0.712 0.477 195 −0.360 0.719
rs2786098 C/A CRB1 202 −1.021 0.307 158 −1.886 0.059
rs2244012 A/G RAD50 188 +0.941 0.347 159 +1.242 0.214
FBAT was used to test for association using the additive model [17]. SNP single nucleotide polymorphism, MAF minor allele frequency, Fam number of families in
analysis (≥10 families). Severity = BTS classification (1–5) [18], SPT = positive skin prick test to one or more allergen. Bonferroni correction, P < 9.1×10-4 considered
significant (bold).
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cer histone marks (rs12709365 and rs13380815 both
ZPBP2/intronic and identified in cell line GM12878),
rs4795399 (GSDMB/intronic) was identified in a HepG2
cell line and also located in a DNase site identified in a
human hepatocyte cell line (Huh7.5) and a human leu-
kaemic cell line (CMK). While no SNPs were predicted
to occur in a protein binding regions, 14 SNPs were pre-
dicted to alter regulatory binding motifs (Table 6).
Analysis of asthma eQTL data
We searched for the eleven SNPs genotyped as part of this
study in turn using the mRNA by SNP browser resource,
looking to see whether the SNP was associated with the
effect meeting genome-wide significance (p < 10-8). In-
formation for three of the SNPs (rs230548/GSDMB,
rs2886098/CRB1 and rs2244012/RAD50) was not covered
by the database and there was no information for SNPs in
LD with these. Another two SNPs were also not covered
by the database, however there was information for a SNP
in high LD. For rs11078927/GSDMB, rs10445308 was in
LD (r2 = 1.0) and this SNP showed genome-wide signifi-
cance with multiple ORMDL3 probes (all C-allele);
223259_at (p = 4.4×10-13, LOD= 11.39, H2 = 14.75) and
probe 235136_at (p = 8.0×10-12, LOD = 10.16, H2 = 13.3)
with average ORMDL3 (p = 3.9×10-22, LOD = 20.32, H2 =
26.36). For rs3771166/IL18R1, rs54988956 was in LD
(r2 = 0.96), but this was not associated with genome-wide
significance with any probe. For the other six SNPs, there
was no genome-wide significance. Using the University of
Chicago eQTL resource, data was available for the two
GSDMB SNPs (rs2305480 and rs11078927) which pro-
vided some evidence that these were eQTLs and exon-
QTLs in lymphoblastoid cell lines, monocytes, liver, brainand T-cells. More specifically, both rs2305480 and
rs11078927 were eQTL for IKZF3, ORMDL3 and
an exon-QTL for KRT222P, NR1D1 and ORMDL3. Only
three of our eleven genotyped SNPs (rs2305480/GSDMB,
rs3939286/IL33 and rs744910/SMAD3) were included in
the genotyping platform for the genome-wide search
for eQTL in 1,111 human lung samples [21]. None of these
SNPs were found in the reported data meeting 10% False
Discovery Rate (FDR). As a further analysis we also
searched this resource for any of the SNPs in high LD
(r2 = 1) with our genotyped SNPs. rs1337167/CRB1 met the
10% FDR. This intron SNP was predicted to alter an AP-1
transcription factor binding site according to HaploReg.
Discussion
GWAS have been successful in identifying susceptibility
genes for asthma through the use of large scale popula-
tion cohorts and replication approaches [2-7]. However,
there remains a need to determine the contribution of
these polymorphisms to clinically relevant endpoints in
asthma as opposed to disease diagnosis. We adopted a
two step process where we selected SNPs from key genes
in the Caucasian population which have met genome-
wide significance and/or with replication, namely eleven
SNPs in the following genes; ORMDL3/GSDMB, IL33,
IL18R/IL1RL1, SMAD3, IL2RB, PDE4D, CRB1 and RAD50.
These SNPs were genotyped in a UK asthma family cohort
with at least two affected siblings, to test for association
with clinically relevant endpoints in asthma. Our data pro-
vide support for the original GSDMB association; however
SNPs in the other genes did not show association after
correction for multiple testing. Secondly, as these SNPs
have previously shown association at a genome-wide level,
we also investigated the potential for these SNPs and
Table 5 Analysis of key GWAS SNPs with data from ENCODE
SNP Gene locus/
location
Number of SNPs in LD
(r2 = 1) (no.)
GERP Conservation Enhancer histone marks
(no. of SNPs in regions)
DNase
(no. of SNPs in regions)
Proteins bound
(no. of SNPs in regions)
Motifs changed
(no. of SNPs with
motif changed
regions)
(no. of SNPs conserved)
rs2305480 C/T GSDMB/Ser311Pro 26 2 3 1 0 14
rs11078927 C/T GSDMB/intronic 26 2 3 1 0 14
rs1342326 T/G IL33/5′-region 7 0 1 2 2 4
rs3939286 G/A IL33/5′-region 1 0 0 0 0 1
rs3771166 C/T IL18R1/intronic 16 0 2 1 0 9
rs1420101 G/A IL1RL1/intronic 6 1 2 1 1 1
rs744910 A/G SMAD3/intronic 3 0 1 2 2 1
rs2284033 A/G IL2RB/intronic 3 0 0 3 0 1
rs1588265 A/G PDE4D/intronic 14 2 0 1 0 5
rs2786098 C/A CRB1/intronic 11 0 0 3 0 7
rs2244012 A/G RAD50/intronic 51 2 6 9 5 25
The 11 SNPs genotyped as part of this study were entered into the HaploReg tool to investigate whether SNPs in the same LD block were likely to affect chromatin structure and regulatory element binding motifs.
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Table 6 Analysis of the GSDMB LD block (r2 =1) using data from ENCODE
SNP Gene locus/location Chromosomal
location (hg19)
GERP
conservation (Y/N)
Enhancer
histone marks
DNase Proteins
bound
Motifs changed
rs12709365 A/G ZPBP2/intronic 17:38027400 N GM12878 N N N
rs13380815 A/G ZPBP2/intronic 17:38027583 N GM12878 N N N
rs11870965 T/A ZPBP2/intronic 17:38030205 N N N N Myb
rs10852935 C/T ZPBP2/synonymous 17:38031674 Y N N N N
rs10852936 C/T ZPBP2/intronic 17:38031714 N N N N Foxp1, Foxq1
rs36095411 T/G ZPBP2/intronic 17:38031865 N N N N 9 motifs altered
rs34189114 C/T ZPBP2/intronic 17:38032460 N N N N N
rs35736272 T/C ZPBP2/intronic 17:38032680 Y N N N N
rs9907088 G/A ZPBP2/downstream 17:38035116 N N N N Sox
rs36038753 G/T ZPBP2/downstream 17:38035370 N N N N Dobox4
rs35569035 C/T ZPBP2/downstream 17:38036524 N N N N Pax4
rs9904624 A/G ZPBP2/downstream 17:38036586 N N N N N
rs12232497 T/C Intergenic 17:38040119 N N N N N
rs12232498 T/C Intergenic 17:38040363 N N N N Lhx3
rs12941333 C/T Intergenic 17:38040534 N N N N Pou3f3, Pou2f1
rs2872507 G/A Intergenic 17:38040763 N N N N N
rs12936409 C/T Intergenic 17:38043649 N N N N N
rs8069176 G/A GSDMB/downstream 17:38057197 N N N N Gfi1, Mafk, Pax4
rs4795399 T/C GSDMB/intronic 17:38061439 N HepG2 Huh7.5,CMK N Pxx6, Pax
rs2305480 G/A GSDMB/Ser311Pro 17:38062196 N N N N N
rs62067034 C/T GSDMB/intronic 17:38063738 N N N N SREBP, LXR
rs11078927 C/T GSDMB/intronic 17:38064405 N N N N N
rs11078928 T/C GSDMB/intronic 17:38064469 N N N N Foxp1
rs4795400 C/T GSDMB/intronic 17:38067020 N N N N N
rs77749396 G/C GSDMB/intronic 17:38073840 N N N N ZNF219
rs9303279 G/C GSDMB/intronic 17:38073968 N N N N Obox3
The two GSDMB SNPs genotyped as part of this study (rs2305480 and rs110788927) were part of a wider LD block containing 26 SNPs in total spanning
46,568 bp. These SNPs were analysed using HaploReg to see if they atlered any binding sites for regulatory elements or other proteins and also whether they
affected chromatin states and their conservation according to GERP. The CEU frequency from 1000 Genomes Project =0.48 for all SNPs. CMK: human leukaemic
cell line; GERP genomic evolutionary rate profiling score; GM12878: lymphoblastoid cell line; GSDMB gasdermin-domain containing protein family B; HepG2:
human hepatocellular liver carcinoma cell line; Huh7.5: human hepatocellular cell line; ZPBP2 zona pellucid binding protein 2 gene. SNPs genotyped in the current
study are shown in bold.
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motifs/binding sites to try to assign potential function to
these associations. This analysis used recently reported
data from the ENCODE project. These data support the
hypothesis that SNPs associated in GWAS may be tagging
SNPs for the actual causative variant, but also provide ten-
tative evidence that these genotyped SNPs may themselves
play a functional role e.g. GSDMB rs2305480 (Ser311Pro).
GWAS have the advantage over linkage studies in that
they can identify polymorphisms with small effect sizes
and localise smaller susceptibility loci as LD only generally
spans <500 kb [22]. Since the identification of childhood
asthma associated variants on chromosome 17q21 [2],
many other GWAS have been completed in different pop-
ulations implicating variants spanning different genes (seeabove). One problem with these studies lies in defining the
contribution of these associated variants to clinical end-
points in asthma. To this end we have completed a SNP
for SNP analysis of key variants identified in the Caucasian
population meeting genome-wide significance or where
there was replication, focussing on GWAS from 2007–
2011 (Table 1). We utilised a well characterised UK family
based asthma cohort [15] to test for association with
asthma diagnosis and the following clinical endpoints:
FEV1 (% predicted), BHR (to methacholine), BTS defined
severity and positive SPT to one or more allergens, see
[15]. These data show significant association for the two
GSDMB SNPs; rs2305480 (Ser311Pro) and rs11078927
(intron) across more than one phenotype, with other pheno-
types showing association which does not reach significance
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cate and extend previous findings [2,6] and identify this
chromosome 17 locus as containing genetic determinants
underlying multiple clinical features of asthma, including
FEV1 (% Predicted) and disease severity defined by BTS.
These two polymorphisms are in high LD suggesting these
associations represent a single locus. The BHR association
(rs2305480) is supported by different SNPs in this gene
also showing association with this phenotype, albeit in dif-
ferent ethnic populations [23,24]. Interestingly, a recent
study has found association between rs2305480 and
wheezing phenotypes in asthmatic children, but did not
find association with intermediate phenotypes such as
atopy or lung function [25].
When interpreting the results of GWAS, the associ-
ated variant could be tagging another variant in a larger
region of LD [26]. This is particularly important as it is
common that only a few variants in a haplotype block
are present on genotyping platforms. Methods such as
imputation and using genotyping data from the 1000
Genomes project can help to further characterise these
patterns [27]. However, once these variants are identified
it is still necessary to assign potential function and with
many associated variants from GWAS residing in non-
transcribed regions, they are likely to play a regulatory
role in gene expression. We used HaploReg [14] to
screen chromatin data, conservation data and regulatory
motif databases which was obtained from the ENCODE
project to see if any biological plausible role could be
assigned to the SNPs genotyped in this study and those
SNPs which were in LD with r2 = 1. Our results show
that these SNPs in LD can potentially lead to changes in
regulatory element binding motifs affecting the tran-
scription of genes positively or negatively and there is
also the suggestion that alterations in enhancer histone
marks or DNase sites could be affected. The non-
synonymous SNP (Ser 311 Pro) is predicted to be dele-
terious to protein structure (Polyphen) in Gasdermin B
suggesting a potential functional mechanism altering
protein function. This may be occurring at the mRNA
level (altering the efficiency of splicing) as this poly-
morphism is predicted to be located in an exonic spli-
cing enchancer site (FuncPred). Both GSDMB SNPs are
in high LD with several SNPs spanning ZPBPZ and
GSDMB which result in alterations in enhancer and
transcription factor binding sites. However the rs2305480
and rs11078927 SNPs themselves are not predicted to
have any regulatory role (ENCODE data). Gasdermin-
family proteins have been implicated in TGFβ1 signalling
and epithelial cell apoptosis [28], with increased airway
cell apoptosis reported in severe asthma [29]. The ex-
tended chromosome 17 locus has also been implicated
previously as containing SNPs associated with asthma
spanning three main genes; ZPBP2/GSDMB/ORMDL3and it is still unclear which genes/polymorphisms underlie
these associations. The finding that the GSDMB SNPs in-
cluding a non-synonymous SNP are particularly relevant
to clinical endpoints including lung function, BHR and se-
verity in our childhood asthma cohort is interesting as few
recent studies have genotyped this GWAS SNP or investi-
gated clinical outcomes with the same criteria such as
BTS used in this study [24,30]. However, a recent study
has investigated the effect of rs7216389 (which is in link-
age disequilibrium with both GSDMB SNPs in this study)
with respect to severe asthma subjects classified with
poorly controlled disease whilst taking high doses of
inhaled corticosteroids, long-acting bronchodilators and
short acting β2 agonists and showed association [31].
Similarly, while not meeting genome-wide association sig-
nificance, we have previously provided evidence that
rs2305480 is associated with severe asthma (p = 5.5×10-5,
[32]), although we do acknowledge that the criteria for
BTS severity is defined in part by lung function and so this
association with severe asthma may be related to a syner-
gistic effect. These data support previous studies that
identified the chromosome 17 locus as containing markers
of childhood onset disease [2,6,24,30], BHR [24] and ele-
vated total serum IgE [24] in diverse ethnic populations.
Interestingly, no other SNP survived correction for
multiple testing for any phenotype analysed, including
asthma diagnosis and there was no indication of any
other SNP showing a trend towards significance. CRB1
rs2786098 (p = 0.089 in the current study) has shown
replicated association in multiple childhood cohorts, but
did not reach statistical significance in our study. Per-
haps this lack of association may be due to power (MAF
0.22, see earlier). One potential explanation for the lack
of association for asthma and related phenotypes for the
majority of SNPs is that many of the SNPs/genes were
identified in adult asthma populations and the relative
contribution to childhood asthma remains unclear at
this time. However, in the results not meeting con-
ventional correction for multiple testing, IL33 SNP
rs1342326G (25.7 kb from gene transcription start site
(TSS)) showed a level of association with atopic asthma
defined by positive skin prick test and clinical diagnosis
(p = 0.0097, Table 4). These data are in line with the ac-
cumulating evidence suggesting a role of IL33 in allergic
mechanisms in asthma (Reviewed in [33]) although we
cannot exclude that this is a false positive. Similarly,
while not surviving correction, suggestive evidence for
SNP associations for CRB1/BHR, IL18R/severity and
IL33/SPT were apparent (p < 0.05), which may represent
true associations.
Studies have shown the potential for GWAS SNPs to be
tagging SNPs associated with eQTL [10]. Our analyses did
provide some support for this particularly for the two
GSDMB SNPs (rs2305480 and rs11078927) when eQTL
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sues. These eQTL analyses identified regulation of mul-
tiple genes in the region, demonstrating the need for
further work to define the biology underlying these gen-
etic signals.
It is important to note the limitations of our study,
while a SNP for SNP approach focussed to the pivotal
SNPs from the GWAS has strengths to directly replicate
and extend previous findings we acknowledge the as-
sumption that the linkage disequilibrium pattern be-
tween the discovery Caucasian population and our UK
population will be the same, which may at least in part
explain the inability to detect associations with all vari-
ants. Similarly, we did not genotype all GWA significant
SNPs identified in each of the regions. We acknowledge
the reduced power of the current study using 370 fam-
ilies is a limitation potentially explaining while several
SNPs showed nominal significance and did not meet
stringent statistical criteria. A cohort of 602 families
would be required to provide a power of 0.99 for the
lowest MAF observed in the current study (relative risk
of 1.5 and significance level of 0.05). We also acknow-
ledge that the design of this study compared to discovery
cohorts using case/control design also has reduced
power, however we consider the use of an alternative as-
sociation design i.e. family based to those previously
published a strength. Furthermore the lack of assessing
gene-environment interactions in GWAS and the
current study may also account for not replicating previ-
ous observed effects due to differential environmental
exposures between study populations. Finally, the poten-
tial for winners curse bias is also possible for direct rep-
lication of e.g. association with asthma diagnosis.
Conclusions
In summary, this study has provided a greater insight
into the relative contribution of asthma GWAS SNPs to
clinically relevant endpoints in asthmatic children and
further defines the diverse role of GSDMB SNPs particu-
larly in lung function and disease severity.
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